New perspectives on the neurodevelopmental effects of SSRIs

Trends in Pharmacological Sciences

Volumn 31, Issue 2, 2010, Pages 60-65

  Homberg, Judith R ^a   Schubert, Dirk ^a   Gaspar, Patricia ^b  

^a RADBOUD UNIVERSITY   (Netherlands)

^b INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

5 CHLORO 1 (3 DIMETHYLAMINOPROPYL) 1 (4 FLUOROPHENYL)PHTHALAN; SEROTONIN; SEROTONIN RECEPTOR AFFECTING AGENT; SEROTONIN TRANSPORTER; SEROTONIN UPTAKE INHIBITOR; UNCLASSIFIED DRUG;

AGGRESSION; ANXIETY; ANXIETY DISORDER; ARTICLE; BEHAVIOR CHANGE; BEHAVIOR DISORDER; BRAIN DEVELOPMENT; BRAIN REGION; CHRONIC DRUG ADMINISTRATION; COGNITIVE DEFECT; CONGESTIVE CARDIOMYOPATHY; DEPRESSION; DEVELOPMENTAL DISORDER; DOWN REGULATION; DRUG EXPOSURE; EXPLORATORY BEHAVIOR; HUMAN; MOTOR DEVELOPMENT; NERVE CELL DIFFERENTIATION; NERVE CELL MEMBRANE POTENTIAL; NERVE CELL NETWORK; NEUROTOXICITY; NONHUMAN; PHENOTYPE; PLACE PREFERENCE; PRENATAL EXPOSURE; PRIORITY JOURNAL; REM SLEEP; SENSORY SYSTEM; SEXUAL BEHAVIOR; SIGNAL TRANSDUCTION; SOMATOSENSORY CORTEX; SPATIAL DISCRIMINATION; TARGET CELL; VASODILATATION;

ANIMALS; BEHAVIOR, ANIMAL; BRAIN; FEMALE; FETUS; HUMANS; MICE; PREGNANCY; PROMOTER REGIONS, GENETIC; RATS; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; SEROTONIN UPTAKE INHIBITORS; SIGNAL TRANSDUCTION;

EID: 75449100367     PISSN: 01656147     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tips.2009.11.003     Document Type: Article

References (64)

1. Krishnan V., et al. The molecular neurobiology of depression. Nature 455 (2008) 894-902
2. Nonacs R., et al. Assessment and treatment of depression during pregnancy: an update. Psychiatr. Clin. North Am. 26 (2003) 547-562
3. Bennett H.A., et al. Prevalence of depression during pregnancy: systematic review. Obstet. Gynecol. 103 (2004) 698-709
4. Ververs T., et al. Prevalence and patterns of antidepressant drug use during pregnancy. Eur. J. Clin. Pharmacol. 62 (2006) 863-870
5. Rampono J., et al. A pilot study of newer antidepressant concentrations in cord and maternal serum and possible effects in the neonate. Int. J. Neuropsychopharmacol. 7 (2004) 329-334
6. Kristensen J.H., et al. Distribution and excretion of fluoxetine and norfluoxetine in human milk. Br. J. Clin. Pharmacol. 48 (1999) 521-527
7. Alwan S., et al. Safety of selective serotonin reuptake inhibitors in pregnancy. CNS Drugs 23 (2009) 493-509
8. Chambers C.D., et al. Selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn. N. Engl. J. Med. 354 (2006) 579-587
9. Koren G., et al. Adverse effects in neonates exposed to SSRIs and SNRI in late gestation - Motherisk Update 2008. Can. J. Clin. Pharmacol. 16 (2009) e66-e67
10. Ansorge M.S., et al. Early-life blockade of the 5-HT transporter alters emotional behavior in adult mice. Science 306 (2004) 879-881
11. Casper R.C., et al. Follow-up of children of depressed mothers exposed or not exposed to antidepressant drugs during pregnancy. J. Pediatr. 142 (2003) 402-408
12. Noorlander C.W., et al. Modulation of serotonin transporter function during fetal development causes dilated heart cardiomyopathy and lifelong behavioral abnormalities. PLoS One 3 (2008) e2782
13. Popa D., et al. Lasting syndrome of depression produced by reduction in serotonin uptake during postnatal development: evidence from sleep, stress, and behavior. J. Neurosci. 28 (2008) 3546-3554
14. Gaspar P., et al. The developmental role of serotonin: news from mouse molecular genetics. Nat. Rev. Neurosci. 4 (2003) 1002-1012
15. Narboux-Nême N., et al. Serotonin transporter transgenic (SERTcre) mouse line reveals developmental targets of serotonin specific reuptake inhibitors (SSRIs). Neuropharmacology 55 (2008) 994-1005
16. Berbel P., et al. Role of thyroid hormones in the maturation and organisation of rat barrel cortex. Neuroscience 107 (2001) 383-394
17. Verney C., et al. Changing distribution of monoaminergic markers in the developing human cerebral cortex with special emphasis on the serotonin transporter. Anat. Rec. 267 (2002) 87-93
18. Lebrand C., et al. Transitory uptake of serotonin in the developing sensory pathways of the common marmoset. J. Comp. Neurol. 499 (2006) 677-689
19. Bonnin A., et al. Serotonin modulates the response of embryonic thalamocortical axons to netrin-1. Nat. Neurosci. 10 (2007) 588-597
20. Nicol X., et al. Requirement of adenylate cyclase 1 for the ephrin-A5-dependent retraction of exuberant retinal axons. J. Neurosci. 26 (2006) 862-872
21. Cornea-Hebert V., et al. Cellular and subcellular distribution of the serotonin 5-HT2A receptor in the central nervous system of adult rat. J. Comp. Neurol. 409 (1999) 187-209
22. Stankovski L., et al. Developmental cell death is enhanced in the cerebral cortex of mice lacking the brain vesicular monoamine transporter. J. Neurosci. 27 (2007) 1315-1324
23. Vitalis T., et al. Embryonic depletion of serotonin affects cortical development. Eur. J. Neurosci. 26 (2007) 331-344
24. Alexandre C., et al. Early life blockade of 5-hydroxytryptamine 1A receptors normalizes sleep and depression-like behavior in adult knock-out mice lacking the serotonin transporter. J. Neurosci. 26 (2006) 5554-5564
25. Vorhees C.V., et al. A developmental neurotoxicity evaluation of the effects of prenatal exposure to fluoxetine in rats. Fundam. Appl. Toxicol. 23 (1994) 194-205
26. Cabrera T.M., et al. Delayed decreases in brain 5-hydroxytryptamine2A/2C receptor density and function in male rat progeny following prenatal fluoxetine. J. Pharmacol. Exp. Ther. 269 (1994) 637-645
27. Hansen H.H., et al. Long-term effects on serotonin transporter mRNA expression of chronic neonatal exposure to a serotonin reuptake inhibitor. Eur. J. Pharmacol. 352 (1998) 307-315
28. Cabrera-Vera T.M., et al. Effect of prenatal fluoxetine (Prozac) exposure on brain serotonin neurons in prepubescent and adult male rat offspring. J. Pharmacol. Exp. Ther. 280 (1997) 138-145
29. Hansen H.H., et al. Neonatal administration of the selective serotonin reuptake inhibitor Lu 10-134-C increases forced swimming-induced immobility in adult rats: a putative animal model of depression?. J. Pharmacol. Exp. Ther. 283 (1997) 1333-1341
30. Manhães de Castro R., et al. Reduction of intraspecific aggression in adult rats by neonatal treatment with a selective serotonin reuptake inhibitor. Braz. J. Med. Biol. Res. 34 (2001) 121-124
31. Maciag D., et al. Neonatal antidepressant exposure has lasting effects on behavior and serotonin circuitry. Neuropsychopharmacology 31 (2006) 47-57
32. Lee L.J. Neonatal fluoxetine exposure affects the neuronal structure in the somatosensory cortex and somatosensory-related behaviors in adolescent rats. Neurotox. Res. 15 (2009) 212-223
33. Bairy K.L., et al. Developmental and behavioral consequences of prenatal fluoxetine. Pharmacology 79 (2007) 1-11
34. Lisboa S.F., et al. Behavioral evaluation of male and female mice pups exposed to fluoxetine during pregnancy and lactation. Pharmacology 80 (2007) 49-56
35. Forcelli P.A., et al. Teratogenic effects of maternal antidepressant exposure on neural substrates of drug-seeking behavior in offspring. Addict. Biol. 13 (2008) 52-62
36. Kalueff, A.V. et al. Conserved role for the serotonin transporter gene in rat and mouse neurobehavioral endophenotypes. Neurosci. Biobehav. Rev. [epub ahead of print, doi:10/1016j/neubiorev.2009.08.003]
37. Homberg J.R., et al. Adaptations in pre- and postsynaptic 5-HT1A receptor function and cocaine supersensitivity in serotonin transporter knockout rats. Psychopharmacology (Berl.) 200 (2008) 367-380
38. Vogel C., et al. Absence of thermal hyperalgesia in serotonin transporter-deficient mice. J. Neurosci. 23 (2003) 708-715
39. Woolsey T.A., et al. The structural organization of layer IV in the somatosensory region (SI) of mouse cerebral cortex. The description of a cortical field composed of discrete cytoarchitectonic units. Brain Res. 17 (1970) 205-242
40. Persico A.M., et al. Barrel pattern formation requires serotonin uptake by thalamocortical afferents, and not vesicular monoamine release. J. Neurosci. 21 (2001) 6862-6873
41. Salichon N., et al. Excessive activation of serotonin (5-HT) 1B receptors disrupts the formation of sensory maps in monoamine oxidase a and 5-ht transporter knock-out mice. J. Neurosci. 21 (2001) 884-896
42. Altamura C., et al. Altered neocortical cell density and layer thickness in serotonin transporter knockout mice: a quantitation study. Cereb. Cortex 17 (2007) 1394-1401
43. Esaki T., et al. Developmental disruption of serotonin transporter function impairs cerebral responses to whisker stimulation in mice. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 5582-5587
44. Schubert D., et al. Mapping functional connectivity in barrel-related columns reveals layer- and cell type-specific microcircuits. Brain Struct. Funct. 212 (2007) 107-119
45. Hariri A.R., et al. Genetics of emotional regulation: the role of the serotonin transporter in neural function. Trends Cogn. Sci. 10 (2006) 182-191
46. Heinz A., et al. Amygdala-prefrontal coupling depends on a genetic variation of the serotonin transporter. Nat. Neurosci. 8 (2005) 20-21
47. Pezawas L., et al. 5-HTTLPR polymorphism impacts human cingulate-amygdala interactions: a genetic susceptibility mechanism for depression. Nat. Neurosci. 8 (2005) 828-834
48. Wellman C.L., et al. Impaired stress-coping and fear extinction and abnormal corticolimbic morphology in serotonin transporter knock-out mice. J. Neurosci. 27 (2007) 684-691
49. Persico A.M., et al. Reduced programmed cell death in brains of serotonin transporter knockout mice. Neuroreport 14 (2003) 341-344
50. Lesch K.P., et al. Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region. Science 274 (1996) 1527-1531
51. Mueller, A. et al. (2009) The role of the serotonin transporter polymorphism for the endocrine stress response in newborns. Psychoneuroendocrinology. [epub ahead of print, doi:10.1016j/psyneuen.2009.07.002]
52. Canli T., et al. Long story short: the serotonin transporter in emotion regulation and social cognition. Nat. Neurosci. 10 (2007) 1103-1109
53. Serretti A., et al. Meta-analysis of serotonin transporter gene promoter polymorphism (5-HTTLPR) association with selective serotonin reuptake inhibitor efficacy in depressed patients. Mol. Psychiatry 12 (2007) 247-257
54. Rampono J., et al. Placental transfer of SSRI and SNRI antidepressants and effects on the neonate. Pharmacopsychiatry 42 (2009) 95-100
55. Wichman C.L., et al. Congenital heart disease associated with selective serotonin reuptake inhibitor use during pregnancy. Mayo Clin. Proc. 84 (2009) 23-27
56. Einarson A., et al. Evaluation of the risk of congenital cardiovascular defects associated with use of paroxetine during pregnancy. Am. J. Psychiatry 165 (2008) 749-752
57. Nulman I., et al. Child development following exposure to tricyclic antidepressants or fluoxetine throughout fetal life: a prospective, controlled study. Am. J. Psychiatry 159 (2002) 1889-1895
58. Oberlander T.F., et al. Pain reactivity in 2-month-old infants after prenatal and postnatal serotonin reuptake inhibitor medication exposure. Pediatrics 115 (2005) 411-425
59. Glassman R.B. Behavioral specializations of SI and SII cortex: a comparative examination of the neural logic of touch in rats, cats, and other mammals. Exp. Neurol. 125 (1994) 134-141
60. Ivarsson M., et al. Antidepressants and REM sleep in Wistar-Kyoto and Sprague-Dawley rats. Eur. J. Pharmacol. 522 (2005) 63-71
61. Mochizucki D. Serotonin and noradrenaline reuptake inhibitors in animal models of pain. Hum. Psychopharmacol. 19 Suppl. 1 (2004) S15-S19
62. Valluzzi J.A., et al. Effects of fluoxetine on hippocampal-dependent and hippocampal-independent learning tasks. Behav. Pharmacol. 18 (2007) 507-513
63. Pacher P., et al. Review of cardiovascular effects of fluoxetine, a selective serotonin reuptake inhibitor, compared to tricyclic antidepressants. Curr. Med. Chem. 5 (1998) 381-390
64. Romijn H.J., et al. At what age is the developing cerebral cortex of the rat comparable to that of the full-term newborn human baby?. Early Hum. Dev. 26 (1991) 61-67